CLEVELAND and INDIANAPOLIS, February 12, 2018 – Allinaire Therapeutics has been awarded a Phase I Small Business Technology Transfer grant from the National Heart, Lung and Blood Institute in the amount of $281,155. This funding will support the development of a novel therapeutic for the treatment of viral-associated lung injury. Allinaire’s aim is to develop new drug therapies for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.
In 2016, Allinaire was formed by BioMotiv, the for-profit drug development accelerator associated with the Harrington Project for Discovery & Development, Indiana University Research & Technology Corp (IURTC), BioCrossroads, and Innovate Indiana. In addition, Allinaire has received several grant awards to support development of its technologies from the Department of Defense and the National Institutes of Health.